News A re-brand for US generics and biosimilars sector Body will campaign to "Keep Medicines in Reach"
News NICE rejects second Alexion ultra-rare disease drug NHS will not fund Kanuma for rare disease LAL-D.
News Norgine rejoins ABPI after eight year absence ABPI says Norgine's support will be important during Brexit.
News Acacia ready to file its anti-vomiting treatment Potential launch in 2018 if FDA approves Baremsis.
News Biotech leaders unite against Trump travel ban Spokesman also causes confusion over pricing policy.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
